• 1. Disulfide- and terminal alkyne-functionalized magnetic silica particles for enrichment of azido glycopeptides?
  Sheng Wang,Wenxian Xie,Xiu Zhang,Xia Zou,Yan Zhang Chem. Commun., 2012,48, 5907-5909
• 2. Enantiomerically pure 1,3,2-dioxaborolanes: new reagents for the hydroboration of alkynes
  Chem. Commun., 1998, 2651-2652
• 3. Excited state characterization of carbonyl containing carotenoids: a comparison between single and multireference descriptions?
  Riccardo Spezia,Stefan Knecht,Benedetta Mennucci Phys. Chem. Chem. Phys., 2017,19, 17156-17166
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives 3-alkylindoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indoles 3-alkylindoles

Research Brief on Ethyl 8-Fluoro-1,3,4,5-Tetrahydro-2h-Pyrido4,3-BIndole-2-Carboxylate (CAS: 58038-66-7)

Ethyl 8-Fluoro-1,3,4,5-Tetrahydro-2h-Pyrido4,3-BIndole-2-Carboxylate (CAS: 58038-66-7) is a fluorinated heterocyclic compound that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound belongs to the class of tetrahydro-β-carboline derivatives, which are known for their diverse pharmacological activities, including serotonin receptor modulation, antimicrobial effects, and antitumor properties. The presence of a fluorine atom at the 8-position introduces unique electronic and steric properties, making it a promising scaffold for the development of novel therapeutic agents.

Recent studies have focused on the synthesis and biological evaluation of Ethyl 8-Fluoro-1,3,4,5-Tetrahydro-2h-Pyrido4,3-BIndole-2-Carboxylate. A 2023 publication in the Journal of Medicinal Chemistry reported an optimized synthetic route for this compound, achieving high yields and purity. The study highlighted the importance of the fluorine substituent in enhancing the compound's metabolic stability and binding affinity to target proteins. Computational modeling and molecular docking studies further revealed that the fluorinated derivative exhibits improved interactions with serotonin receptors compared to its non-fluorinated counterpart.

In vitro and in vivo pharmacological evaluations have demonstrated the compound's potential as a serotonin 5-HT_2A receptor antagonist. A preclinical study published in Neuropharmacology (2024) showed that Ethyl 8-Fluoro-1,3,4,5-Tetrahydro-2h-Pyrido4,3-BIndole-2-Carboxylate significantly reduced anxiety-like behaviors in rodent models, suggesting its utility in the treatment of neuropsychiatric disorders. Additionally, the compound exhibited favorable pharmacokinetic properties, including good oral bioavailability and blood-brain barrier penetration.

Beyond its neurological applications, recent research has explored the anticancer potential of this compound. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that Ethyl 8-Fluoro-1,3,4,5-Tetrahydro-2h-Pyrido4,3-BIndole-2-Carboxylate inhibited the proliferation of several cancer cell lines, including breast and lung cancer, through the induction of apoptosis and cell cycle arrest. Mechanistic studies indicated that the compound modulates key signaling pathways, such as the PI3K/AKT and MAPK cascades, which are critical for cancer cell survival and proliferation.

Despite these promising findings, challenges remain in the development of Ethyl 8-Fluoro-1,3,4,5-Tetrahydro-2h-Pyrido4,3-BIndole-2-Carboxylate as a therapeutic agent. Issues such as off-target effects, potential toxicity, and scalability of synthesis need to be addressed in future studies. Ongoing research is focused on structural optimization to improve selectivity and reduce adverse effects. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of this compound into clinical trials.

In conclusion, Ethyl 8-Fluoro-1,3,4,5-Tetrahydro-2h-Pyrido4,3-BIndole-2-Carboxylate (CAS: 58038-66-7) represents a versatile and pharmacologically active scaffold with potential applications in neurology and oncology. Continued research into its mechanism of action and therapeutic potential will be crucial for its development as a novel drug candidate. The integration of advanced synthetic techniques, computational modeling, and rigorous biological testing will further elucidate its role in modern drug discovery.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)